Elutia announces full U.S. commercial launch of EluPro

Elutia (ELUT) announced the U.S. commercial launch of EluPro, an FDA-cleared antibiotic-eluting biomatrix designed for use with cardiac implantable electronic devices and neurostimulators. This full launch follows a successful pilot program in which EluPro was introduced at select hospitals, demonstrating strong physician adoption and positive patient outcomes. During this initial phase, Elutia has submitted EluPro for approval with 136 hospital value analysis committees, initiated sales at 70 institutions and established key relationships with four prominent group purchasing organizations, including Premier and S3P. In an early indication of positive customer reception, envelope orders have increased over 50% in accounts following EluPro VAC approval.